Which Of The Following Diseases Is Classified As A Spondyloarthropathy

Spondyloarthropathies, also known as spondyloarthritis, represent a group of inflammatory diseases that primarily affect the spine and the sites where tendons and ligaments attach to bone. While the term may sound technical, the condition is relatively common, affecting up to 2 % of the adult population worldwide. Understanding which specific illnesses fall under this umbrella is essential for accurate diagnosis, appropriate treatment, and effective patient education. In this article we will explore the defining features of spondyloarthropathies, examine the most frequently encountered diseases that meet the classification criteria, and provide a clear answer to the question: which of the following diseases is classified as a spondyloarthropathy?

What Defines a Spondyloarthropathy?

The hallmark of a spondyloarthropathy is inflammation of the entheses—the points where tendons or ligaments insert into bone. This distinguishes the group from other forms of arthritis that primarily target the synovial lining of joints. Key clinical and radiographic features include:

• Axial involvement – chronic low‑back pain, morning stiffness, and limited spinal mobility.
• Peripheral joint disease – asymmetric oligoarthritis, often affecting the lower extremities.
• Extra‑articular manifestations – uveitis, psoriasis, inflammatory bowel disease, and sacroiliitis.
• Genetic association – a strong link with the HLA‑B27 allele, though not all patients are HLA‑B27 positive.

The International Organization for the Study of Spondyloarthritis (IOSS) and the Assessment of Spondyloarthritis International Society (ASAS) have refined classification criteria that combine clinical, laboratory, and imaging data. These criteria are applied to a set of recognized disease entities.

Common Diseases Classified as SpondyloarthropathiesThe spectrum of spondyloarthropathies includes several distinct but overlapping conditions. Below is a concise list of the most prevalent disorders that meet the classification standards:

1. Ankylosing Spondylitis (AS) 2. Non‑Radiographic Axial Spondyloarthritis (nr‑AS) 3. Reactive Arthritis 4. Psoriatic Arthritis (PsA)
2. Enteropathic Arthritis (associated with Crohn’s disease or ulcerative colitis)
3. Undifferentiated Spondyloarthritis

Each of these entities shares common pathogenic pathways, yet they differ in clinical presentation, extra‑articular features, and prognosis. Recognizing these distinctions helps clinicians tailor management strategies and provides patients with realistic expectations.

In‑Depth Look at Each Condition### Ankylosing Spondylitis (AS)

Ankylosing spondylitis is the prototypical axial spondyloarthropathy. It typically begins in early adulthood with insidious onset of chronic low‑back pain that improves with activity but worsens with rest. Over time, persistent inflammation can lead to syndesmophytes, enthesophytes, and eventual bamboo‑spine formation, where the vertebral bodies fuse. Extra‑articular manifestations may include anterior uveitis, which occurs in up to 30 % of patients.

Non‑Radiographic Axial Spondyloarthritis (nr‑AS)

Approximately 30 % of patients with axial spondyloarthritis lack definitive radiographic changes at presentation. The term non‑radiographic reflects the absence of sacroiliitis on conventional X‑rays, but magnetic resonance imaging (MRI) often reveals active inflammation in the sacroiliac joints or spinal entheses. Early recognition of nr‑AS is crucial because biologic therapies can halt disease progression before irreversible damage occurs.

Reactive Arthritis

Reactive arthritis develops after an infection of the gastrointestinal or genitourinary tract, most commonly due to Campylobacter, Shigella, or Salmonella species, or after urethral infection with Chlamydia trachomatis. The classic triad—arthritis, conjunctivitis, and urethritis—is often accompanied by skin lesions such as keratoderma blennorrhagica. Unlike AS, reactive arthritis is usually self‑limiting, though a subset of patients develop chronic joint disease.

Psoriatic Arthritis (PsA)

Psoriatic arthritis occurs in up to 30 % of individuals with psoriasis and can involve any joint, including the distal interphalangeal joints, axial skeleton, and entheses. The disease is characterized by asymmetric oligoarthritis, dactylitis (sausage‑digit swelling), and nail changes (pitting, onycholysis). When PsA involves the spine, it is classified as an axial spondyloarthropathy, but the pattern of involvement may differ from classic AS.

Enteropathic ArthritisIn patients with inflammatory bowel disease (IBD), arthritis can manifest as an extra‑intestinal manifestation. Enteropathic arthritis may present as peripheral arthritis that mimics rheumatoid arthritis or as an axial spondyloarthropathy with sacroiliitis. The joint disease often parallels the activity of the underlying gastrointestinal inflammation, suggesting a shared immune dysregulation.

Undifferentiated Spondyloarthritis

When clinical features meet the ASAS criteria but do not fully satisfy the classification for any specific disease, the term undifferentiated spondyloarthritis is used. This category serves as a diagnostic placeholder, encouraging further evaluation for hidden features such as subclinical inflammation on MRI or a positive HLA‑B27 test.

How to Identify Which Disease Is a Spondyloarthropathy

When faced with a multiple‑choice question such as “which of the following diseases is classified as a spondyloarthropathy?”, the answer hinges on recognizing the disease’s alignment with the defining characteristics outlined above. Below is a typical set of answer options that might appear on a board‑style exam, followed by a brief rationale for the correct choice.

Correct answer: C – Ankylosing spondylitis.
The rationale is straightforward: AS exhibits chronic axial inflammation, sacroiliitis on imaging, strong HLA‑B27 association, and a tendency toward spinal ankylosis—all hallmarks of the spondyloarthropathy group.

Diagnostic Work‑up for Spondyloarthropathies

Accurate diagnosis relies on a systematic approach that integrates clinical history, physical examination, laboratory testing, and imaging. The following steps are commonly employed:

1. History and Physical Examination
   • Look for chronic inflammatory back pain (≥ 3

1. Historyand Physical Examination

• Inquire about the onset, duration, and pattern of pain—particularly whether it improves with activity and worsens with rest.
• Assess for extra‑articular clues such as psoriasis, uveitis, colitis, or family history of rheumatic disease.
• Perform a focused musculoskeletal exam, noting tenderness over the sacroiliac joints, limited lumbar flexion, and enthesional tenderness at sites like the tibial tuberosity or plantar fascia.

2. Laboratory Evaluation

• Inflammatory markers – Elevated C‑reactive protein (CRP) or erythrocyte sedimentation rate (ESR) suggest systemic inflammation, though normal values do not exclude a spondyloarthropathy.
• Genetic testing – HLA‑B27 positivity raises suspicion, especially in young males with axial disease, but a negative result does not rule out the condition.
• Serology – Rheumatoid factor and anti‑CCP are typically negative, helping to differentiate from rheumatoid arthritis. ### 3. Imaging Modalities
  | Modality | What It Reveals | Typical Findings | |----------|----------------|------------------| | Plain radiographs | Bone remodeling, joint space narrowing | Sacroiliac joint erosion, syndesmophytes, vertebral corner fractures | | Computed tomography (CT) | High‑resolution detail of complex joint anatomy | Cortical bone lesions, subtle erosions not visible on X‑ray | | Magnetic resonance imaging (MRI) | Active inflammation, enthesitis, soft‑tissue involvement | Bone marrow edema in the sacroiliac joints or spinal facets, synovitis, tendon inflammation | | Ultrasound | Enthesitis and peripheral joint synovitis | Power‑Doppler signal indicating vascularization of inflamed entheses |

Early MRI changes—such as bone marrow edema—often precede radiographic damage, allowing clinicians to intervene before irreversible structural injury occurs.

4. Classification Algorithms

When a patient presents with inflammatory back pain or peripheral arthritis, clinicians usually apply the Assessment of SpondyloArthritis International Society (ASAS) criteria. The algorithm proceeds as follows:

1. Clinical suspicion – Inflammatory back pain lasting > 3 months, or peripheral arthritis with a pattern of joint involvement typical of spondyloarthritis. 2. Imaging evidence – Sacroiliitis on X‑ray or MRI (unilateral or bilateral).
2. Laboratory markers – Positive HLA‑B27 or elevated CRP.
3. Response to therapy – Improvement after an NSAID trial can further support the diagnosis.

If any three of the five items are met, the patient is classified as having axial or peripheral spondyloarthritis, prompting further work‑up for the specific subtype.

5. Management Principles | Step | Intervention | Rationale |

|------|--------------|-----------| | First‑line | NSAIDs at therapeutic doses | Rapid analgesia and reduction of inflammatory activity; most patients experience symptomatic relief. | | Second‑line | Conventional disease‑modifying agents (e.g., sulfasalazine) | Useful for peripheral arthritis or enthesitis when NSAIDs are insufficient; modest efficacy in axial disease. | | Biologic therapy | TNF‑α inhibitors (e.g., etanercept, adalimumab) or IL‑17 blockers (e.g., secukinumab) | Target the cytokine pathways most implicated in spondyloarthropathy pathogenesis; highly effective for refractory axial disease and often improve skin or bowel symptoms. | | Non‑pharmacologic | Structured exercise programs, physiotherapy, and ergonomic modifications | Preserve spinal mobility, improve posture, and reduce functional limitation. | | Surgical | Joint replacement or osteotomy in end‑stage, fixed deformities | Reserved for selected cases where conservative measures fail to prevent disability. |

Treatment goals focus on controlling pain, preserving function, preventing structural damage, and addressing extra‑articular manifestations. Regular reassessment—typically every 3–6 months—allows timely adjustments when response wanes or new symptoms emerge.

6. Special Considerations

• Pediatric spondyloarthritis – Presentation may be dominated by enthesitis‑related arthritis of the lower limbs; early recognition prevents chronic joint damage.
• **Pregnancy and

...management during pregnancy requires careful medication selection to balance maternal disease control with fetal safety. NSAIDs are generally avoided in the third trimester due to risks of premature closure of the ductus arteriosus. While most TNF inhibitors are considered relatively safe in pregnancy (particularly certolizumab, which has minimal placental transfer), IL-17 blockers lack sufficient safety data and are typically discontinued preconception. Disease flares during pregnancy should be managed with the safest available options, often involving close coordination between rheumatology, obstetrics, and pediatrics. Breastfeeding is usually compatible with most biologic agents, though individual risk-benefit assessment is essential.

Elderly patients often present with diagnostic challenges, as inflammatory back pain may be mistaken for degenerative spine disease, and comorbidities can mask or exacerbate symptoms. A lower threshold for MRI and careful interpretation of inflammatory markers (which may be blunted by age) are recommended. Treatment selection must account for polypharmacy risks, renal function, and infection susceptibility, often favoring stepwise escalation with close monitoring.

Patients with concomitant inflammatory bowel disease (IBD) or psoriasis may influence therapeutic choices. For instance, IL-17 inhibitors can exacerbate IBD, making TNF inhibitors a preferred option in such cases. Conversely, those with predominant skin involvement may benefit from IL-17 blockade. A multidisciplinary approach ensures cohesive management of all disease facets.

Conclusion

Spondyloarthritis represents a spectrum of interrelated inflammatory conditions where early recognition—using tools like the ASAS criteria—and prompt, tailored intervention are paramount to preventing irreversible damage and preserving quality of life. The therapeutic landscape has evolved from solely relying on NSAIDs to a sophisticated, mechanism-based approach incorporating conventional agents and targeted biologics, all integrated with essential non-pharmacological strategies. Management must remain dynamic, with regular reassessment to adapt to disease fluctuations, extra-articular manifestations, and life-stage-specific considerations such as pregnancy or aging. Ultimately, a patient-centered, multidisciplinary model that addresses both the physical and psychosocial burdens of spondyloarthritis offers the best prospect for long-term functional preservation and improved outcomes. Ongoing research into novel pathways and personalized medicine promises further refinement of these strategies in the years ahead.